Context Therapeutics has announced the completion of a transaction to buy out all existing royalty obligations associated with its drug candidate, CT-202. The company has not disclosed the financial terms of this agreement.
This acquisition of royalty obligations means that Context Therapeutics will no longer be required to pay a percentage of its revenue or profits from CT-202 to external parties. The company has stated that this move is intended to simplify its financial structure.
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. CT-202 is currently undergoing development, with the specifics of its indication and stage of clinical trials not detailed in the available information.
